Formerly known as Healthcare Investment Opportunities. Please refer to the HIO thread for previous posts.

Collagen Solutions signs exclusive licence
StockMarketWire.com
Collagen Solutions has announced the exclusive licensing of intellectual property generated in the laboratory of Professor Robert Brown at University College London (UCL). The core patent, already granted in the US, describes a breakthrough platform technology for the production of stronger, more durable, living collagen-based 'tissues'. Using the novel process covered by the licence, the production process creates collagen materials with a significant range of additional clinical applications in the replacement of tissues such as skin, tendon, bone and even cartilage, blood vessels and nerve conduits.

The most significant advantage of these natural, living materials are their physical strength and rapid production times. This means that surgeons will be able to implant them sooner, whilst at the same time, there is the potential to have the novel collagen-based products customised to the precise needs of the patient and their injury.

From a business and manufacturing perspective, there is also the advantage that the collagen sources used for these materials are many times more efficient than current comparable collagen feed-stocks. These advantages will inevitably assist other areas of clinical research into technologies for rapid and specific fabrication of novel tissues using bio-lamination or 3D bio-printing which are presently very difficult due to the lack of suitable support materials. It is envisaged that this platform technology will enable the creation of a new generation of collagen based tissue replacements for use in a far wider patient population than is presently feasible with added potential to expedite both autologous and allogeneic cell therapies.

Chief executive Dr Stewart White said: "This licence is hugely significant for Collagen Solutions as it places us at the very centre of the future of collagen engineering.

"With our own know-how and exclusive access to the technology developed in Professor Brown's laboratory, we believe that this combination will make us the 'go to' company for any company looking to create biomaterial-based tissue regeneration and repair products. The licensing of this IP is designed to integrate our specialist collagen capabilities with the diverse biomedical capacity and global research standing of UCL and will drive forward patient benefit in many new areas of regenerative medicine."



Story provided by StockMarketWire.com

Jellagen Collaboration
RNS
RNS Number : 5369U
Collagen Solutions PLC
17 October 2014

Collagen Solutions Plc

(the "Company" or the "Group")



Funded Research Collaboration with Jellagen

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it will be collaborating with Jellagen Pty Ltd ('Jellagen') as part of a Small firms' Merit Award for Research and Technology ('SMART') grant to improve the production of medical grade collagen derived from jellyfish.



The SMART funding from Innovate UK amounts to almost £100k and will help Jellagen improve their product quality as well as the efficiency of collagen extraction from jellyfish. This funding will also be used to investigate, alongside Collagen Solutions, Swansea University's Centre for Nano Health and University College London ('UCL'), the utilisation of jellyfish derived, medical grade, Type II and Type V collagen for the fabrication of various medical devices. This will include the generation of specific biological data on the use of this improved collagen for applications in bone grafts



Stewart White, CEO of Collagen Solutions commented: "We require access to consistent supplies of medical grade collagen derived from jellyfish and therefore made a strategic investment in Jellagen when it was founded. We see this as a reliable and renewable source of novel medical grade collagen which we can then help to fabricate into potential medical products. This development work will be carried out with the support of our in-house teams in San Diego and Glasgow. The SMART funding will allow Collagen Solutions to provide further support in order to develop novel commercial forms of Jellyfish collagen for Jellagen."

 


Collagen Solutions pre-tax losses rise

StockMarketWire.com

Collagen Solutions posts pre-tax losses of £560,831 for the six months to he end of September - up from £62,631 last time - and announced the proposed acquisition of New Zealand based Southern Lights Biomaterials and a placing to raise £6m.

Revenue for the first six months was £143,213 (2013: £NIL). Administrative expenses were £467,672, (2013: £62,631) reflecting the costs of operating a public company and the related regulatory costs. Selling and marketing costs were £161,171 (2013: £NIL), LBITDA for the first six months was (£522,144) (2013: (£62,631)), and the loss per share was (0.88)p (2013: (0.15)p). Net cash used in operations during the period was £482,476. The Group's cash balances at 30 September 2014 were £927,094 (31 March 2014: £1,491,660).

The company says the proposed acquisition of New Zealand based Southern Lights Ventures 2002 Limited (trading as Southern Lights Biomaterials) for a total maximum consideration of NZ$12m (c. £6m) in cash and shares is a logical strategic extension and complementary acquisition that provides additional security of supply of high grade collagen.

The company also announced a conditional placing to raise £6m at 7p, representing c. 50.13% of the enlarged issued share capital at admission. Directors are subscribing for a total of 9,285,714 Placing Shares



Story provided by StockMarketWire.com

Collagen Solutions PLC

24 November 2014

Collagen Solutions Plc

(the "Company" or the "Group")

Grant of Option

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is pleased to announce that it has today granted an option to Gillian Black, Chief Financial Officer, over up to 1,000,000 new ordinary shares of one penny each in the Company ("Ordinary Shares") pursuant to the terms of the EMI Share Option Scheme ("Option") exercisable at a price of 7.75p.

The Option will become exercisable from 1 January 2017 subject to Ms Black remaining in employment with the Company (or any other member of the Company's Group) and the achievement of either of the following two targets:

1) the market value of an Ordinary Share being equal to or greater than 27p on any date after the date of grant; and

2) the Company's earnings per share in any financial year which ends after the date of grant being equal to or greater than 1p.

Following the grant of the Option, the total number of options outstanding over Ordinary Shares is 5,938,349 equivalent to 9.30% of the Company's existing issued share capital.

Southern Lights Biomaterials Acquisition Completed

RNS

RNS Number : 3045Z
Collagen Solutions PLC
10 December 2014
 


Collagen Solutions Plc
(the "Company" or the "Group")
 
 Southern Lights Biomaterials Acquisition Completed
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the completion of the acquisition of Southern Light Biomaterials ('SLB'), a profitable business converting collagen and other biological materials into value added products which are supplied to clients for further processing or by direct sales to customers.
 
The acquisition of SLB has further de-risked the Company's business model and is a logical strategic extension and complementary in nature to the Company's existing business model.
 
Benefits of the combined business:
 
·     Profit added (EBITDA of £273,911 in year ended March 2014)
·     Increased IP and know-how around biomaterial development and manufacture
·     Secure raw material from registered BSE free sources
·     Focus on creating higher value formulations of collagen
·     Critical mass as a global supplier with increased geographic reach
·     Security of production and increased capacity via additional production site
·     Wider range of processed raw materials, e.g. pericardium
·     Combined international operations in North America, Europe and New Zealand
·     New regional strength in Asia
·     Turn-key solutions using biomaterials from "source to device"
·     Geoff Bennett joins Collagen Solutions board as Chief Business Officer
 
Collagen Solutions and SLB have a complementary history, culture and strategy which makes the merger of the two businesses a logical move. The benefits of the merger include security of source material as SLB provides processed and semi processed bovine biomaterials, secured exclusively from New Zealand, a country the World Organisation for Animal Health describes as a 'negligible BSE risk' country.
 
SLB is based in the North Island of New Zealand, and benefits from being close to a readily available and consistent source of high quality and safe tissue. Like Collagen Solutions, SLB is a provider of processed and semi-processed biomaterials to medical device manufacturers and serves an increasing international client base with particular strengths in South Korea and other Asian countries where Collagen Solutions had no previous presence.
 
The acquisition gives the enlarged Group access to additional manufacturing capacity of medical grade collagen.  With the combined expertise of the two companies and access to North America and Asia it would be expected that more value added products will be demanded, increasing the price per gram that can be charged by the enlarged Group.
 
Overall the Group now:
 
·     Trades in Europe, North America and Asia
·     Benefits from a number of long term client arrangements 
·     Has a product catalogue which includes various grades of medical collagen as well as a range of other biomaterials that will be offered to the expanded Group's customer base
·     Manufactures collagen products  which are present in a range of registered products 
·     Produces medical grade collagen which should be of increased interest to medical device manufacturers
·     Has increased capacity and capability to manufacture medical grade biomaterials
·     Is working on a number of development projects which will benefit from the newly formed Collagen Solutions Group, which the Directors believe will result in higher value added sales
 
Commenting on the first day of trading of the combined Group's shares, Dr Stewart White, CEO of Collagen Solutions said: "This is a very good acquisition for Collagen Solutions.  The enlarged Group is well positioned to grow as the demand for medical grade collagen and collagen-based materials find increasing use in regenerative medicine and diagnostics. This represents a very significant step in completing the strategic aim of having a market capitalisation for the Group of £100m by 2020."
 
For additional information on Collagen Solutions, please visit www.collagensolutions.co.uk

Giltspur Nominees just bought a large chunk here.

Reyker Nominees bought in.

Contract signed with Kyeron

RNS

RNS Number : 7068Z
Collagen Solutions PLC
15 December 2014
 


Collagen Solutions Plc
15 December 2014                                    (the "Company" or " Collagen Solutions")
 
Commercial supply of fibrous collagen powder agreed with KYERON
for the development of a wound management device
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its subsidiary Collagen Solutions (UK) Limited has signed an agreement with KYERON Medical Innovations (KYERON) to develop and supply fibrous collagen powder for the manufacture of a wound management device.
 
Collagen Solutions is committed to providing the highest quality, medical grade biomaterials to support medical devices and other products for regenerative medicine across a wide range of applications and clinical indications. Collagen Solutions will use its expanded development capability in the UK, US and New Zealand to develop a specific grade of fibrous collagen powder which KYERON will then formulate into a product for commercialization in the growing wound management market.
 
KYERON was formed in 2007 and is a private Dutch biomaterials company based in Enschede, the Netherlands, specialising in developing solutions to medical needs. Its products use the innovative biomaterial knowledge of the Company to produce a range of products for various orthopaedic, neurosurgical and periodontal tissue grafting procedures.
 
Dr Stewart White, Chief Executive Officer of Collagen Solutions said, "This agreement to provide our medical grade fibrous collagen is an excellent example of how we now bring together our development capability and world-recognised expertise in the manufacture of medical grade collagen products. We are capable of providing clients with a product that meets their needs precisely. We are pleased to see that KYERON has the confidence in the capabilities of Collagen Solutions to identify and manufacture consistently and in sufficient quantity, collagen products to satisfy their commercial needs as demand for their products grow.  More importantly, we can support KYERON with respect to regulatory submissions for new products containing our collagen."
 
Chief Executive Officer of KYERON, Mr. Ronny Masselink said, "We are a manufacturer of innovative products using the best available raw materials. This is a great opportunity for us to work closely with a collagen specialist that can provide us with the highest grade materials consistently. Collagen Solutions will be our partner in the development of a fibrous collagen powder to benefit those patients suffering acute and chronic wounds. We see Collagen Solutions as our preferred supplier for these raw materials for this and other collagen-based biomaterials such as bone graft substitutes. Working with them we now have access to the required state-of-art collagen technology to create our next generation of innovative products."
 

Nice uptrend on the chart since the beginning of November - will it continue?

Helium Rising Stars Fund just bought in - 10.7million.

New contract to supply Desu Medical

RNS

RNS Number : 3876A
Collagen Solutions PLC
22 December 2014
 


22 December 2014          
 
Collagen Solutions Plc
(the "Company" or the "Group")
 
New contract with Desu Medical for the supply of soluble collagen
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its subsidiary Collagen Solutions (UK) Limited has agreed a contract with Desu Medical to supply soluble collagen. This agreement is for the manufacturing of brain dura and spinal fusion implants which will be used in the treatment of dura/spinal injuries by stimulating enhanced dura/bone generation through the use of high concentration collagen. Dura is the thick membrane that surrounds and protects the brain and spinal cord.
 
Collagen Solutions is committed to providing the highest quality collagen-based biomaterials to support medical devices and regenerative medical interventions across a wide range of applications and clinical indications. The announcement confirms that its soluble collagen will be used in the production of Desu Medical's brain and spinal implants DECOLL® and DEBONE®.
 
Dr Stewart White, CEO of Collagen Solutions plc said: "We are pleased to announce that we have reached an agreement for the supply of our soluble collagen product to Desu Medical. This agreement is the culmination of a long association with Desu Medical during which we have been supplying developmental quantities of medical grade collagen. Winning this contract is based on our ability to convince such an established Company that we can supply a medical grade collagen suitable for manufacturing their products consistently and to order, for the life of the product line. It is important for companies to secure their source of the collagen early in the commercialisation process as this will become part of the regulatory submissions for their products around the World. The long term provision of our medical grade collagen for an increasing number of products begins to unlock the value that we have in our manufacturing capabilities."
 
Dr Mehmet Sorar, CEO of Desu Medical said: "We are equally pleased to announce our agreement with Collagen Solutions. Our aim is to make our products - DEBONE® and DECOLL®, which contain up to 90% soluble collagen - leading brands in the market. We hope that our collaboration will last for many years to come."
 

Updated broker's note on the website:
www.collagensolutions.com

tick, tick,tick

Contract signed with Globus Medical Inc.

RNS

RNS Number : 2193B
Collagen Solutions PLC
05 January 2015
 


Collagen Solutions Plc
5 January 2015                            (the "Company" or the "Group")
 
Commercial supply of a collagen powder to Globus Medical Inc.
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its subsidiary Collagen Solutions (UK) Limited has agreed a contract with Globus Medical Inc. (NYSE: GMED) to supply fibrous collagen powder for use in the manufacture of their bone grafting products.
 
Globus Medical Inc. is a leading musculoskeletal implant manufacturer driving significant technological advancements across a complete suite of spinal products. Founded in 2003, with sales of $434.5 million in 2013, Globus' single-minded focus on advancing spinal surgery has made it one of the fastest growing companies in the history of orthopaedics. Globus is driven to utilise superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders.
 
Dr Stewart White, Chief Executive Officer of Collagen Solutions plc said: "Our agreement with Globus today comes at an exciting time for the company.  Globus utilising our fibrous collagen powder is another example of how Collagen Solutions will realise its value, through strong and long partnerships with customers, founded on early stage commitment and the provision of quality, competitive collagen materials to ensure the provision of cost effective health care for patients."
 
Chief Executive Officer of Globus Medical Inc., David Paul said: "Collagen Solutions' technical and quality expertise is value-adding to our product and is the basis on which we have made this commitment today. Collagen Solutions is an important material provider in our supply chain and we look forward to a long association with the company."
 

CEO Presents at OneMedForum

RNS

RNS Number : 4626B
Collagen Solutions PLC
07 January 2015
 


7 January 2015  
 
Collagen Solutions Plc
(the "Company" or the "Group")
 
CEO to present at the OneMedForum
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its CEO, Stewart White, will be presenting at OneMedForum on 12 January 2015 in San Francisco.
 
Formerly known as the H&Q (Hambrecht & Quist) Conference, OneMedForum is an industry summit for healthcare financiers, industry executives and growth companies from around the world. The objective of OneMedForum is to assemble the most promising companies and technologies in health and medicine and help them to successfully connect with the industry's leading investors and healthcare executives.
 
Dr Stewart White, Chief Executive Officer of Collagen Solutions plc said: "We were pleased to be invited to attend and present at this very prestigious conference. The Company has made significant progress in the last twelve months demonstrating both its global reach and diversified business model.  This is an ideal forum to present these achievements to a global audience of companies and investors."
 
Presentations and interviews with executives will be available on a webcast and thereafter archived.  Details of how to access the webcast and archive will be made available ahead of the meeting.
 

Investor Presentation

RNS

RNS Number : 7071B
Collagen Solutions PLC
09 January 2015
 


Collagen Solutions Plc
(the "Company" or the "Group")
 
Investor Teach-In
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces it will be holding a teach-in for investors and analysts on Tuesday, 3rd February 2015. The event will be held at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm.
A presentation will be given by Dr Stewart White, CEO and Dr Kevin Wilson, Non-Executive Director of Collagen Solutions. The presentation will include an overview of the Company and an outline of their strategy to deliver value for shareholders. This will be followed by drinks and canapés.
To register for the event, please email collagen@walbrookpr.com or call the Walbrook PR team below.
 
 
Enquiries:
 
Collagen Solutions Plc
 
Stewart White, CEO
Tel: 0141 558 2008
 
 
Zeus Capital (Nominated Adviser and Broker)  
 
Ross Andrews / John Depasquale (Corporate Finance)
Tel: 0161 831 1512
Alex Davies (Institutional Sales)
Tel: 020 7533 7727
 
 
Panmure Gordon & Co (Joint Broker)
Robert Naylor (Corporate Finance)                                                                                            
Tel: 0207 8862 714
Tel: 020 7886 2905
Maisie Atkinson (Corporate Broking)
 
 
 
Walbrook PR Ltd
Tel: 020 7933 8780 or collagen@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Mike Wort
Mob: 07900 608 002
 
 
 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END

Hi Doodlebug
Whats current thoughts on this? I'm still very much in.. just waiting on several potentials updates hopefully early January... which should get us moving well.
Happy new year to you.

Growth & Innovation Forum 2017


Tuesday 31st January 2017

MEET YOUR NEXT GROWTH COMPANY INVESTMENT

Click here to REGISTER now


Share price performance of some of the companies that attended the last event include:

Cyan +43%

Instem + 44%

Satellite Solutions Worldwide +79%

Summit Therapeutics +32%

XLMedia +46%


The Growth and Innovation Forum, organised in partnership with Cenkos Securities and Shares, is in its 5th year and is the UK's only growth and technology company investment show.

Thousands of investors have attended our previous shows. This year attendees will be able to:

· Learn from industry experts and influencers about the markets, the technology sector and individual companies

· Find out from fund managers how they view the future in 2017 and beyond

· Meet the directors of up to 40 listed growth companies

· Listen to presentations from our expert team of Shares journalists


Key note Speakers at the Show include:

Daniel Coatsworth, Editor - Shares

Russ Mould, Investment Director - AJ Bell

Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust

Simon Strong, Head of Research, Growth Companies - Cenkos Securities

Further keynote speakers to be announced.


Presenting at the Show and available to meet during the day will be a number of listed company CEOs and Directors:

Andrew Newland, CEO - ANGLE

Alastair Smith, CEO - Avacta

Rachel Elias-Jones, CFO - Bango

Keith Butcher, CFO - Blancco Technology Group

Terry Hart, CFO - CityFibre

Simon Cleaver, CEO - CloudCall

Jamal Rushdy, CEO - Collagen Solutions

John Cronin, Executive Chairman - CyanConnode

Philipp Prince, CFO - Defenx

Frontier IP Group

Phil Reason, CEO - Instem

Steve Flavell, co-CEO - LoopUp

Jose Luis Vazquez, CEO - Mirada

Ian Smith, CEO - One pm Finance

Plastics Capital

Mark Braund, CEO - RedstoneConnect

Simon Kings, Executive Director - TP Group

David Richards, Interim Chairman, President, CEO & Co-founder - WANdisco

More companies to be announced.


For more information go to the event website here

REGISTER NOW



The Growth and Innovation Forum is the UK's only growth and technology focussed investment show.


About the show

Do you want to find the next stock market star performer?

Interested in growth and technology focused companies?

Do you want to know how investing really works?

Are you looking to build your wealth through capital growth and income?

Want to take an active role in managing your money?


Come to the Growth and Innovation Forum and connect with top experts who will share their in-depth knowledge of investing and meet directors from fast-growing and technology led London listed companies.

Some of last year's showcased companies gave investors brilliant returns (31/1/17 to 1/12/17).

Bioventix up 78%

Wandisco up 66%

LoopUp up 51%


The show is brought to you by the team at Shares Magazine and AJ Bell in partnership with Cenkos Securities.


Why you should attend


Hear from more than 30 speakers, including top investment experts, fund managers, company executives and renowned journalists from the Shares team

Meet directors of listed firms, fund managers, savings and investment experts

Learn about investment topics suited to a range of investors from novice to expert

Discover more about the most important market issues and strategies for 2018


REGISTER NOW



FREE GIFTS


Get a Growth and Innovation Forum goody bag worth over £140 when you attend!

Goody bag includes:


1) A one year subscription to Shares Magazine digital. Each week you will receive the latest Shares digital weekly magazine where our team of experts will give you a multitude of investment ideas for income and capital growth. You will also gain access to the Shares investor toolkit with live news, LIVE share prices, fund prices, portfolio and research tools (value £120)

2) Volt Power Bank Charger (2200mAh), boosts your device when you're out and about, by simply connecting it with the USB cable. Approximate charging time is 3-4 hours.

3) The new DIY Investor digital e-book written by Andy Bell, CEO of AJ Bell (RRP £17.99)

PLUS all attendees will be entered into free prize draws for:

An all-new Amazon Echo (2nd generation) which connects to Alexa,a cloud-based voice service, to play music, make calls, set alarms and timers, ask questions, check your calendar, weather, traffic and sports scores, manage to-do and shopping lists, control compatible smart home devices, and more.

A Fitbit Alta fitness wrist band, a customisable fitness tracker designed to fit your personal style. Stay motivated by tracking all-day activity – steps, distance, calories burned and active minutes.

A Wired Magazine subscription (one year Print and Digital). WIRED is the magazine about what's next – bringing you the people, the trends and the big ideas that will change our lives. Each month, through thought-provoking features and stunning photography, they explore the next big ideas in science, culture, and business – wherever innovation and new thinking are reshaping our world.

A Design Museum one year pass. The Design Museum is the world's leading museum devoted to contemporary design in every form from architecture and fashion to graphics, product and industrial design. Design Museum members enjoy free unlimited entry to all the museum’s exhibitions and other benefits besides


The Growth and Innovation Forum is free to attend; you simply need to register in advance to secure your ticket. Please click here to order your ticket and tell your friends to come along to the event which is being held on Tuesday 30 January 2018 between 09.00 and 17.30 at the Business Design Centre, 52 Upper Street, Islington, London, N1 0QH. It is well served by public transport with several tube stations on its doorstep.


Hear From

Companies at this event include:

AJ Bell
Cambridge Cognition
Cloudcall
CML Microsystems
Collagen Solutions
Corero Network Security
Creo Medical
CyanConnode
Duke Royalty
EU Supply
FairFX
Getech
Jaywing
Medaphor
Medherant
Mercia Technologies
nDreams
Plastics Capital
PrimaryBid
RedT energy
Smart Metering Systems
Totally
YU Group

+ more companies to be announced


Guest Speakers

Oliver Brown, Investment Director, R.C. Brown Investment Management

Daniel Coatsworth, Editor, Shares Magazine

Steve Frazer, News Editor, Shares Magazine

Russ Mould, Investment Director, AJ Bell

Richard Penny, Fund Manager, Legal & General UK Alpha Trust

Tom Selby, Senior Analyst, AJ Bell

Gervais Williams, Director and Fund Manager, Miton Group


Event timings

Registration: from 09:00
Conference: 09:45 - 17:00
Exhibition: 09:00 - 17:30

REGISTER NOW